Navigation Links
GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
Date:8/28/2012

IRVINE, Calif., Aug. 28, 2012 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

(Photo: http://photos.prnewswire.com/prnh/20120828/AQ63427)

(Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

Hypoxia, a physiological state characterized by reduced oxygen levels, impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the HIF1a transcription factor. In addition to being a natural physiological process, hypoxia and the subsequent accumulation of HIF1a have been shown to significantly contribute to the pathophysiology of multiple diseases including cancer, pulmonary hypertension, myocardial and cerebral ischemia, congenital heart disease and chronic obstructive pulmonary disease. When oxygen becomes limited, prolyl hydroxylase is inhibited, which leads to HIF1a accumulation and translocation to the nucleus. HIF1a then activates transcription of various genes including VEGFA, Glut1 and CA9 that are responsible for the cellular hypoxia response. Therefore, antibodies that can accurately detect HIF1a are valuable research tools for the study of hypoxia and hypoxia-related diseases.

"HIF1a is an important target for biomedical research, but unfortunately many of the antibodies that are currently on the market have been plagued by specificity and stability issues," says Dr. Stephen Kendall. "GeneTex's new HIF1a antibody can withstand multiple freeze/thaw cycles without losing its sensitivity."

GeneTex is proud to introduce this superior antibody against HIF1a that is both highly stable and specific. This antibody has been fully validated for immunocytochemistry/immunofluorescence, immunoprecipitation and western blotting applications. 

For additional information on GeneTex, Inc. and its hypoxia antibodies, please call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/HIF1-alpha-antibody-GTX127309.html.

About GeneTex, Inc.
GeneTex, Inc. is an antibody manufacturer founded by a group of internationally renowned academic scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee. 

Corporate Mission
We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.


'/>"/>
SOURCE GeneTex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AllMobilityScooters.com Launches Blog
2. Selfhelp Community Services and FEGS Health & Human Services Launch New Care Management Company: SinglePoint Care Network to Coordinate Care for Seniors & Others With Chronic Medical Conditions in Managed Long Term Care Market
3. BioWorld Launches Enhanced Biopharma News Site with Data, Analysis
4. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
5. MGC Diagnostics Corporation Launches New Corporate Website and Unveils New Logo
6. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
7. Express Scripts Launches Virtual Coaching To Help Patients Better Understand Therapy
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
9. Omnetics Launches Cable Design for Micro-wire Harnesses in Miniature Electronics
10. Elsevier Launches New Journal: Discourse, Context and Media
11. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):